SCHEDULE 13D/A: Major Shareholders Reduce Stake in Royalty Pharma plc, Selling Over 4.9 Million Shares

Key shareholders, GG Strategic and MGG Strategic, have significantly reduced their holdings in Royalty Pharma plc, selling over 4.9 million Class A Ordinary Shares in recent open market transactions.

Summary

• R & H Trust Co. (Guernsey) Limited and Achille G. Severgnini, as Reporting Persons, filed Amendment No. 6 to their Schedule 13D regarding Royalty Pharma plc's Class A Ordinary Shares.
• The amendment details open market sales of Class A Ordinary Shares by MGG Strategic SICAF SIF S.A. MGG Strategic and GG 1978 SICAF SIF S.A. GG Strategic.
• A total of 4,926,303 Class A Ordinary Shares were sold between March 3, 2025, and May 2, 2025.
• The average price per share for these sales ranged from $31.8208 to $33.9624.
• As of May 2, 2025, MGG Strategic directly holds 15,000,000 Class A Shares, and GG Strategic directly holds 14,926,170 Class A Shares.
• Collectively, the Reporting Persons beneficially own an aggregate of 29,926,170 Class A Shares, representing 6.9% of the outstanding Class A Shares.
• The percentage of beneficial ownership is based on 433,444,937 Class A Shares outstanding as of April 9, 2025.
• The Reporting Persons and board members of the managing entities disclaim beneficial ownership over these shares.

Sentiment

Score: 4

Explanation: The document is a factual report of significant share sales by major shareholders, which is generally perceived as a neutral to slightly negative signal due to the reduction in their stake, without any offsetting positive news or strategic updates.

Negatives

• Significant sales of 4,926,303 Class A Ordinary Shares by major shareholders (GG Strategic and MGG Strategic) could be perceived negatively by the market, indicating a reduction in their conviction or a need for liquidity.
• The sales occurred at varying price points, with some sales occurring at lower average prices than earlier transactions, potentially reflecting market conditions or a desire to offload shares.

Risks

• Large-scale share sales by significant beneficial owners may signal a lack of confidence in the company's future prospects or a shift in investment strategy, which could put downward pressure on the stock price.
• The reduction in beneficial ownership by these entities could decrease their influence over corporate governance or strategic decisions, potentially altering the company's shareholder dynamics.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Royalty Pharma plc's future performance or strategic direction. It is purely a factual update on beneficial ownership and share transactions.

Industry Context

This filing primarily concerns a change in beneficial ownership by specific institutional investors and does not provide broader insights into industry trends within the pharmaceutical royalty sector. However, significant sales by major shareholders can influence investor sentiment towards the company and, by extension, the industry.

Stakeholder Impact

• Shareholders: The significant sales by major beneficial owners could lead to increased market volatility or downward pressure on the stock price, impacting shareholder value.
• Investment Professionals: Provides updated information on institutional holdings and trading activity, which is crucial for investment analysis and portfolio management.

Next Steps

• The Reporting Persons undertake to provide, upon request of the staff of the Securities and Exchange Commission, full information regarding the number of shares of Class A Ordinary Shares sold at each separate price within the price ranges set forth in the sales table.

Key Dates

Keywords

Royalty Pharma plc, Class A Ordinary Shares, Schedule 13D, Beneficial Ownership, Share Sales, Institutional Investors, SEC Filing, GG Strategic, MGG Strategic